Skip to main content
SpringerLink
Log in

What is the clinical impact of macrolide resistance?

  • Published:
Current Infectious Disease Reports Aims and scope Submit manuscript

Abstract

Respiratory tract infections are treated empirically. Treatment is based on the likely pathogens and their antibiotic susceptibility. The most common respiratory tract pathogen is Streptococcus pneumoniae. In the United States, approximately 25% to 30% of S. pneumoniae are resistant to erythromycin and other macrolides. There are two mechanisms of resistance: ribosomal methylation that causes high-level resistance, and an efflux pump that causes low-level resistance. Macrolides are ineffective in animal models that use pneumococcal isolates with the methylase- or efflux-mediated resistance mechanisms. There are many case reports that describe clinical failure and isolation of a macrolide-resistant pneumococcus while a patient receives macrolide treatment. Two recent studies that included macrolide-susceptible and macrolideresistant pneumococci showed that breakthrough bacteremia in patients receiving macrolide treatment occurred only with macrolide-resistant isolates. Study of bacteremic disease ensures the pathogenic role of the pneumococcus; however, it underestimates the true clinical impact of macrolide resistance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Cherry DK, Burt CW, Woodwell DA: National Ambulatory Medical Care Survey: 2001 summary. Adv Data 2003, 337:1–44.

    PubMed  Google Scholar 

  2. Hall MJ, DeFrances CJ: 2001 National Hospital Discharge Survey. Adv Data 2003, 332:1–18.

    Google Scholar 

  3. Fang GD, Fine M, Orloff J, et al.: New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases. Medicine 1990, 69:307–316.

    Article  PubMed  CAS  Google Scholar 

  4. Ostergaard L, Andersen PL: Etiology of community-acquired pneumonia. Evaluation by transtracheal aspiration, blood culture, or serology. Chest 1993, 104:1400–1407.

    PubMed  CAS  Google Scholar 

  5. Niederman MS, Mandell LA, Anzueto A, et al.: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001, 163:1730–1754.

    PubMed  CAS  Google Scholar 

  6. Bartlett JG, Dowell SF, Mandell LA, et al.: Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000, 31:347–382.

    Article  PubMed  CAS  Google Scholar 

  7. Jacobs MR, Felmingham D, Appelbaum PC, Gruneberg RN: The Alexander Project 1998–2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003, 52:229–246.

    Article  PubMed  CAS  Google Scholar 

  8. LeClercq R, Courvalin P: Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification. Antimicrob Agents Chemother 1991, 35:1267–1272.

    PubMed  CAS  Google Scholar 

  9. Sutcliffe J, Tait-Kamradt A, Wondrack L: Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrob Agents Chemother 1996, 40:1817–1824.

    PubMed  CAS  Google Scholar 

  10. Farrell DJ, Douthwaite S, Morrissey I, et al.: Macrolide resistance by ribosomal mutation in clinical isolates of Streptococcus pneumoniae from the PROTEKT 1999–2000 study. Antimicrob Agents Chemother 2003, 47:1777–1783.

    Article  PubMed  CAS  Google Scholar 

  11. Spika JS, Facklam RR, Plikaytis BD, et al.: Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979–1987. J Infect Dis 1991, 163:1273–1278.

    PubMed  CAS  Google Scholar 

  12. Lonks JR, Medeiros AA: High rate of erythromycin and clarithromycin resistance among Streptococcus pneumoniae isolates from blood cultures from Providence, R.I. Antimicrob Agents Chemother 1993, 37:1742–1745.

    PubMed  CAS  Google Scholar 

  13. Thornsberry C, Sahm DF, Kelly LJ, et al.: Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999–2000. Clin Infect Dis 2002, 34(Suppl 1):S4-S16.

    Article  PubMed  Google Scholar 

  14. Hyde TB, Gay K, Stephens DS, et al.: Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA 2001, 286:1857–1862. This study of invasive pneumococcal isolates shows that the rate of macrolide resistance increased from 10.6% in 1995 to 20.4% in 1999. This increase was caused by isolates with the M phenotype.

    Article  PubMed  CAS  Google Scholar 

  15. Bonnefoy A, Guitton M, Delachaume C, et al.: In vivo efficacy of the new ketolide telithromycin (HMR 3647) in murine infection models. Antimicrob Agents Chemother 2001, 45:1688–1692.

    Article  PubMed  CAS  Google Scholar 

  16. Tessier PR, Kim MK, Zhou W, et al.: Pharmacodynamic assessment of clarithromycin in a murine model of pneumococcal pneumonia. Antimicrob Agents Chemother 2002, 46:1425–1434.

    Article  PubMed  CAS  Google Scholar 

  17. Mitten MJ, Meulbroek J, Nukkala M, et al.: Efficacies of ABT-773, a new ketolide, against experimental bacterial infections. Antimicrob Agents Chemother 2001, 45:2585–2593.

    Article  PubMed  CAS  Google Scholar 

  18. Okamoto H, Miyazaki S, Tateda K, et al.: In vivo efficacy of telithromycin (HMR3647) against Streptococcus pneumoniae and Haemophilus influenzae. Antimicrob Agents Chemother 2001, 45:3250–3252.

    Article  PubMed  CAS  Google Scholar 

  19. Dagan R, Leibovitz E, Fliss DM, et al.: Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children. Antimicrob Agents Chemother 2000, 44:43–50. The authors studied the bacteriologic and clinical efficacy of macrolides in the treatment of otitis media caused by macrolide-susceptible and macrolide-resistant pneumococci.

    PubMed  CAS  Google Scholar 

  20. Dagan R, Johnson CE, McLinn S, et al.: Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media. Pediatr Infect Dis J 2000, 19:95–104. The authors studied the bacteriologic and clinical efficacy of macrolides in the treatment of otitis media caused by macrolide-susceptible and macrolide-resistant pneumococci.

    Article  PubMed  CAS  Google Scholar 

  21. Dixon JMS. Pneumococcus resistant to erythromycin and lincomycin. Lancet 1967, 1:573.

    Article  Google Scholar 

  22. Medoff G: Pneumonia caused by a pneumococcus resistant to erythromycin and lincomycin. Mo Med 1974, 71:496–497.

    PubMed  CAS  Google Scholar 

  23. Champion LA, Wald ER, Luddy RE, Schwartz AD: Streptococcus pneumoniae resistant to erythromycin and clindamycin. J Pediatr 1978, 92:505–506.

    Article  PubMed  CAS  Google Scholar 

  24. Sanchez C, Armengol R, Lite J, et al.: Penicillin-resistant pneumococci and community-acquired pneumonia. Lancet 1992, 339:988.

    Article  PubMed  CAS  Google Scholar 

  25. Jackson MA, Burry VF, Olson LC, et al.: Breakthrough sepsis in macrolide-resistant pneumococcal infection. Pediatr Infect Dis J 1996, 15:1049–1051.

    Article  PubMed  CAS  Google Scholar 

  26. Fogarty C, Goldschmidt R, Bush K: Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin. Clin Infect Dis 2000, 31:613–615. This is a report of three patients who had macrolide-resistant pneumococcal bacteria while receiving azithromycin. One isolate containing the mef gene had low-level macrolide resistance.

    Article  PubMed  CAS  Google Scholar 

  27. Kelley MA, Weber DJ, Gilligan P, Cohen MS: Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis 2000, 31:1008–1011. This is a case study that included three patients who developed breakthrough bacteremia with a macrolide-resistant Pneumococcus while receiving azithromycin or clarithromycin. All isolates had the M phenotype: low-level macrolide resistance (MIC 8 or 16 µg/mL) and susceptible to clindamycin.

    Article  PubMed  CAS  Google Scholar 

  28. Waterer GW, Wunderink RG, Jones CB: Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy. Chest 2000, 118:1839–1840. This is a report of a 49-year-old woman who developed bacteremia with a macrolide-resistant Pneumococcus while receiving intravenous azithromycin.

    Article  PubMed  CAS  Google Scholar 

  29. Musher DM, Dowell ME, Shortridge VD, et al.: Emergence of macrolide resistance during treatment of pneumococcal pneumonia. N Engl J Med 2002, 346:630–631.

    Article  PubMed  Google Scholar 

  30. Lonks JR, Garau J, Gomez L, et al.: Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycinresistant Streptococcus pneumoniae. Clin Infect Dis 2002, 35:556–564. This is a case-control study that examined the development of breakthrough bacteremia with macrolide-susceptible and macrolide-resistant pneumococci in patients receiving a macrolide.

    Article  PubMed  CAS  Google Scholar 

  31. Van Kerkhoven D, Peetermans WE, Verbist L, Verhaegen J:Breakthrough pneumococcal bacteraemia in patients treated with clarithromycin or oral beta-lactams. J Antimicrob Chemother 2003, 51:691–696. This is a study of breakthrough bacteremia that included susceptible and resistant pneumococci.

    Article  PubMed  CAS  Google Scholar 

  32. Heffron R: Complications: Incidence and treatment. In Pneumonia with Special Reference to Pneumococcus lobar Pneumonia. Cambridge, MA: Harvard University Press; 1979:549–561.

    Google Scholar 

  33. Klugman KP, Koornhof HJ, Kuhnle V, et al.: Meningitis and pneumonia due to novel multiply resistant pneumococci. Br Med J (Clin Res Ed) 1986, 292:730.

    Article  CAS  Google Scholar 

  34. Butler JC, Lennox JL, McDougal LK, et al.: Macrolide-resistant pneumococcal endocarditis and epidural abscess that develop during erythromycin therapy. Clin Infect Dis 2003, 36:e19-e25.

    Article  PubMed  Google Scholar 

  35. Perez-Trallero E, Marimon JM, Iglesias L, Larruskain J: Fluoroquinolone and macrolide treatment failure in pneumococcal pneumonia and selection of multidrug-resistant isolates. Emerg Infect Dis 2003, 9:1159–1162.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Miriam Hospital, 164 Summit Avenue, 02906, Providence, RI, USA

    John R. Lonks MD

Authors
  1. John R. Lonks MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lonks, J.R. What is the clinical impact of macrolide resistance?. Curr Infect Dis Rep 6, 7–12 (2004). https://doi.org/10.1007/s11908-004-0018-1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11908-004-0018-1

Keywords

Search

Navigation